Discovery of potent kinase inhibitors with improved pharmacokinetics and safety potentials through structural optimization of dasatinib

Key Points

• The research aims to discover and optimize new kinase inhibitors for better effectiveness and safety.
• Structural optimization of dasatinib to enhance its inhibitory effects.
• Evaluation of pharmacokinetics to assess absorption and metabolism.
• Assessment of safety profiles in preclinical models.
• PDD-87 identified as a highly potent kinase inhibitor.
• Significant improvements observed in pharmacokinetics compared to dasatinib.
• Enhanced safety potentials indicate broader clinical applicability.